Blood Cancer Research Group (BCRG)

What Blood Cancer Research Group (BCRG) does

Blood Cancer Research Group (BCRG) is an academic research entity founded in 2015 in Ostrava, Czech Republic, structured as a joint project between the Medical Faculty of the University of Ostrava and the Hematooncology Department of University Hospital Ostrava. Its functional mandate is translational and clinical research in hematologic malignancies, with a primary focus on multiple myeloma and broader blood cancers. BCRG serves the scientific and clinical community — patients enrolled in investigator-initiated studies, academic collaborators, and the broader hematology research field — rather than commercial end-customers.

BCRG's core scientific outputs are CAR-T and CAR-NK cell therapy programs, supported by access to a hospital-anchored biobank of blood cancer patient samples. The group files patents around its constructs and methods (three applications, one granted European patent EP 4 180 049 A1) and disseminates findings through 56 peer-reviewed publications totaling 716 citations and an H-index of 15. Research is conducted by an interdisciplinary team of senior researchers, PhD students, postdocs, and technicians embedded in a university-hospital clinical environment that provides both patient sample access and translational validation pathways.

The business model is non-commercial: BCRG does not sell products or services. It operates as a grant-funded academic group, with revenue derived entirely from competitive research grants (LERCO cluster funding, G-Rex Grant ~$75K, EHA and IMS travel/awards, and EU funding streams) and institutional support from its university and hospital partners. There are no disclosed licensing revenues, product sales, or industry-sponsored milestones; any future commercialization would likely occur via licensing or spin-out structures built atop the existing IP and clinical data assets.

Name

Blood Cancer Research Group (BCRG)

Legal name

Blood Cancer Research Group

Website

https://bcrg.cz

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Blood Cancer Research Group (BCRG) is an Ostrava, Czech Republic academic research group founded in 2015, jointly operated by the University of Ostrava Medical Faculty and University Hospital Ostrava, focused on translational blood cancer research — primarily multiple myeloma and CAR-T/CAR-NK cell therapy development.

Ownership category

akta.pro rank

Product category

Biomedical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Blood and Organ Banks (621991)

SIC

Services-Engineering, Accounting, Research, Management (8700), Services-Health Services (8000)

akta.pro primary industry

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

akta.pro secondary industries

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD)

Keywords

• Blood cancer research
• CAR-T cell therapy
• Multiple myeloma research
• Immunotherapy research
• Cell therapy development

Headquarters

HQ city

Ostrava

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Research Grants and Funding: BCRG receives funding through national and international grants including LERCO project (CZ.10.03.01/00/22_003/0000003), European Union funding, Czech Science Foundation, European Hematology Association grants, and competitive institutional research funding. Positions are fully funded for doctoral students and postdoctoral researchers.
2. G-Rex Grant (ScaleReady/Wilson Wolf/Bio-Techne): Awarded $75,000 G-Rex Grant from ScaleReady, Wilson Wolf Manufacturing, Bio-Techne, and CellReady for CAR-T and CAR-NK cell therapy development

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

BCRG is an academic biomedical research group that conducts blood cancer research with a primary focus on multiple myeloma. It develops CAR-T and CAR-NK cell immunotherapy platforms alongside CRISPR-based gene editing tools and optogenetic control systems. The group operates as a joint project of the Medical Faculty of the University of Ostrava and the Hematooncology Department of University Hospital Ostrava, conducting translational research programs from discovery through preclinical development.

Product overview

BCRG is a biomedical research institution established in 2015 as a joint project of the Medical Faculty, University of Ostrava and the Hematooncology Department, University Hospital Ostrava. The organization focuses on both basic and pre-clinical research with the main aim to develop novel therapeutic approaches in the field of monoclonal gammopathies and other hematological disorders. BCRG's product portfolio includes off-the-shelf cell-based cancer therapeutics (therapeutic composition with fibrin-based scaffold, NK cells, and mesenchymal stem cells), CAR-T and CAR-NK cell therapy development platforms, hybrid T-cell receptor technologies, and biobank services for biological sample management. The research is organized into multiple specialized labs including Simicek Lab (CAR-based immune synapse research), Jelinek Lab (multiple myeloma precision medicine), Immuno-Biophysics Lab (T cell and NK cell biology), and Alzubi Lab (next-generation CAR immune cell therapies).

Differentiator

Problem solved

Functional benefit

Products and services

• CAR-T cell immunotherapy research program

Quantifiable outcome

• Real-world data from 2,149 Czech patients on autologous stem cell transplantation outcomes published in Haematologica (2026)
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered major and core.

• Czech Myeloma GroupmajorStrategic or Co-development Partner · 1 January 2026Collaborative research network for treatment pattern studies and real-world evidence analysis involving over 2,200 newly diagnosed multiple myeloma patients across Czech Republic centers.
• ScaleReady / Wilson Wolf Manufacturing / Bio-Techne / CellReadycoreStrategic or Co-development Partner · 1 January 2025University Hospital Ostrava awarded $75,000 G-Rex Grant from ScaleReady initiative to support CAR-T and CAR-NK therapy development. The grant accelerates implementation of G-Rex cell expansion technology within the hospital's translational research pipeline, focusing on optimizing upstream cell manufacturing protocols including activation, transduction, and expansion for T and NK cell therapies. Forms cornerstone of ATMP manufacturing capacity building.
• LERCO (Life Environment Research Center Ostrava)coreStrategic or Co-development Partner · 1 January 2024Recently established research hub in Moravian-Silesian region worth 18 billion CZK. BCRG is part of LERCO with Haematooncology program leadership. LERCO provides new research premises and expanded team capacity. LERCO funding supports PhD student and postdoctoral positions for 4+ years.
• University of Ostrava (Medical Faculty)coreStrategic or Co-development Partner · 1 January 2015Joint project establishing BCRG as biomedical centre. Medical Faculty provides academic infrastructure, research facilities, and integration with university education programs including PhD student recruitment and supervision.
• University Hospital Ostrava (Hematooncology Department)coreStrategic or Co-development Partner · 1 January 2015Joint project establishing BCRG with direct access to large collection of patient samples and clinical collaboration. Department provides clinical expertise, patient access, and pathway for translating research findings into clinical applications.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Precision BioSciences: Clinical-stage company developing in vivo gene editing and CAR-T cell therapies using ARCUS gene editing platform. Adjacent to BCRG's CRISPR-based cell therapy approach, with focus on hematological malignancies.
• Adicet Bio: Clinical-stage company developing gamma delta CAR-T cell therapies for hematological and solid tumors. Comparable to BCRG's engineered T-cell therapy approach for multiple myeloma and other blood cancers, with focus on off-the-shelf allogeneic products.
• Mustang Bio: Clinical-stage biotech developing CAR-T cell therapies for hematological malignancies including multiple myeloma. Comparable to BCRG's CAR-T development focus, though operating at commercial scale with ongoing clinical trials.

Direct peers

• Crispr Therapeutics: Clinical-stage company developing CRISPR/Cas9 gene-edited cell therapies including allogeneic CAR-T candidates. Shares BCRG's core thesis that CRISPR-based gene editing enables next-generation cell therapy products, with overlapping hematological malignancy focus.
• Allogene Therapeutics: Clinical-stage biotech pioneering allogeneic CAR-T cell therapies for blood cancers. Comparable to BCRG's allogeneic CAR-T development using non-viral gene editing, though operating at much larger scale with ongoing clinical trials.
• Nkarta Therapeutics: Clinical-stage company developing engineered NK cell therapies for hematological malignancies. Directly overlaps with BCRG's CAR-NK cell therapy development, including similar use of cell expansion technologies and multiple myeloma focus.
• Caribou Biosciences: Clinical-stage company developing allogeneic CAR-T cell therapies using CRISPR-based gene editing (Cas9 and Cas12a chRDNA). Shares BCRG's core technology thesis of CRISPR-mediated precision gene editing for safer allogeneic CAR-T products.
• Cellectis: Clinical-stage biotech developing allogeneic CAR-T cell therapies using TALEN-based gene editing. Directly comparable to BCRG's CAR-T work using non-viral CRISPR-based gene editing for hematological malignancies, with similar focus on off-the-shelf allogeneic products.
• Fate Therapeutics: Clinical-stage biotech developing iPSC-derived NK and T-cell therapies for cancer. Comparable to BCRG's NK-cell therapy programs and off-the-shelf allogeneic cell therapy approach for hematological malignancies.

Others

• Sana Biotechnology: Clinical-stage company developing engineered cell therapies including hypoimmune allogeneic CAR-T cells. Adjacent to BCRG's engineered cell therapy focus, though with broader platform ambitions across cell engineering modalities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bcrg-ostrava

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blood Cancer Research Group (BCRG)